Upgrade to BuyandBill.com Pro to access this report and the complete suite of analytics tools.
| Manufacturer ▼ | Drug Name | Indication | Stage | Status | Route of Administration | Drug Class |
|---|---|---|---|---|---|---|
| Entero Therapeutics Inc Com Par $0.0001 (New) | Oral niclosamide - (RESERVOIR) | COVID-19-related gastrointestinal (GI) infections | Phase 2 | Oral | COVID-19 | |
| Entero Therapeutics Inc Com Par $0.0001 (New) | FW-UP (niclosamide) | Ulcerative Proctitis (UP) and Ulcerative Proctosigmoiditis (UPS) | Phase 2b | oral | Gastroenterology | |
| Entero Therapeutics Inc Com Par $0.0001 (New) | Latiglutenase | Celiac disease | Phase 3 | IND Clearance | Oral | Gastroenterology |
| Entero Therapeutics Inc Com Par $0.0001 (New) | Capeserod | Gastrointestinal (GI) indications | Phase 2 | Trial Planned | Oral | Gastroenterology |
| Entero Therapeutics Inc Com Par $0.0001 (New) | Niclosamide (FW-420) - (PASSPORT) | Colitis and diarrhea in oncology patients | Phase 2a | Oral | Oncology | |
| Epizyme Inc. | TAZVERIK (Tazemetostat) and RITUXAN (rituximab) - (EZH-1401) | Follicular Lymphoma | Phase 2 | Oral Intravenous | Oncology | |
| Epizyme Inc. | TAZVERIK (Tazemetostat) | Adult patients with mesothelioma characterized by BAP1 loss-of-function | Phase 2 | oral | Oncology | |
| ePlus inc. | DocePLUS | Small cell lung cancer | Phase 2 | Trial Completed | Intravenous | Oncology |
